

Acetylamino-caproyl-Val-Thr-Val-Ala-Pro-Val-His-Ile  
(SEQ ID NO:13)

AdamantylNH-CO-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ  
ID NO:13)

$\alpha$ -Naphthyl-NH-CO-Val-Thr-Val-Ala-Pro-Val-His-Ile  
(SEQ ID NO:13)

CBz-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ ID NO:13)

CBz-Phe-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ ID  
NO:14)

Fmoc-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ ID NO:13)

wherein CBz is carbobenzoxy, MeOSuc is  
monomethoxysuccinyl and Fmoc is 9-fluorenylmethoxycarbonyl.

#### REMARKS

The amendment to Figure 1 is made to correct a typographical error in line 3. Approval of this proposed figure correction is respectfully requested.

Applicants have added into the present specification a new paper copy Sequence Listing section according to 37 C.F.R. §1.821(c). Furthermore, attached hereto is a 3 1/2" disk containing the "Sequence Listing" in computer readable form in accordance with 37 C.F.R. §1.821(e).

Applicants have amended the specification to insert SEQ ID NOs, as supported in the present specification. In addition, the specification on page 12 is amended to correct a typographical error. Peptides 4 and 5 are incorrectly indicated as having the sequence Cys<sub>36</sub>-His-Leu-Phe<sub>39</sub> from SEQ ID

NO:3. It is clear from Fig.1 (SEQ ID NO:3) that residues 37-38 should be Leu-His instead of His-Leu. Applicants submit that this correction is fully supported by the specification as originally filed and is not new matter.

The following statement is provided to meet the requirements of 37 C.F.R. §1.821(f) and 1.821(g).

I hereby state, in accordance with 37 C.F.R. §1.821(f), that the content of the attached paper and computer readable copies of the sequence listing are believed to be the same.

I hereby also state, in accordance with 37 C.F.R. §1.821(g), that the submission is not believed to include new matter.


Applicants submit that the present application contains patentable subject matter and therefore urge the examiner to pass the case to issuance.

If the examiner has any questions or comments concerning the above described application, the examiner is urged to contact the undersigned at the phone number below.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By

  
Allen C. Yun  
Registration No. 37,971

ACY:al  
624 Ninth Street, N.W.  
Washington, D.C. 20001  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528

F:\Y\YEDA\Fridkin1\pto\RESPONSE TO NOTICE TO COMPLY.doc

1/2

pGlu-Thr-Asp-Met-Ser-Arg-Lys-Ala-Phe-Val-Phe-Pro-Lys-Glu-Ser-	15
Asp-Thr-Ser-Tyr-Val-Ser-Leu-Lys-Ala-Pro-Leu-Thr-Lys-Pro-Leu	30
Lys-Ala-Phe-Thr-Val-Cys-Leu-His-Phe-Tyr-Thr-Glu-Leu-Ser- <del>Se</del> <sup>u</sup> Ser	45
Thr-Arg-Gly-Tyr-Ser-Ile-Phe-Ser-Tyr-Ala-Thr-Lys-Arg-Gln-Asp-	60
Asn-Glu-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile-Gly-Tyr-Ser-Phe-	75
Thr-Val-Gly-Gly-Ser-Glu-Ile-Leu-Phe-Glu-Val-Pro-Glu-Val-Thr-	90
Val-Ala-Pro-Val-His-Ile-Cys-Thr-Ser-Trp-Glu-Ser-Ala-Ser-Gly-	105
Ile-Val-Glu-Phe-Trp-Val-Asp-Gly-Lys-Pro-Arg-Val-Arg-Lys-Ser-	120
Leu-Lys-Lys-Gly-Tyr-Thr-Val-Gly-Ala-Glu-Ala-Ser-Ile-Ile-Leu-	135
Gly-Gln-Glu-Gln-Asp-Ser-Phe-Gly-Gly-Asn-Phe-Glu-Gly-Ser-Gln-	150
Ser-Leu-Val-Gly-Asp-Ile-Gly-Asn-Val-Asn-Met-Trp-Asp-Phe-Val-	165
Leu-Ser-Pro-Asp-Glu-Ile-Asn-Thr-Ile-Tyr-Leu-Gly-Gly-Pro-Phe-	180
Ser-Pro-Asn-Val-Leu-Asn-Trp-Arg-Ala-Leu-Lys-Tyr-Glu-Val-Gln-	195
Gly-Glu-Val-Phe-Thr-Lys-Pro-Gln-Leu-Trp-Pro-OH	206

Fig. 1